Please assess the completion status of the following clinical trial:

Trial Title: Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All women with symptomatic fibroids or adenomyosis that have requested and been approved for uterine artery embolization~2. Ability to comply with the requirements of the study procedures~Exclusion Criteria:~1. Patients in whom the vascular anatomy prevents access to the superior hypogastric nerve plexus safely~2. Patients who have known allergy to the anesthetic agent~3. Patients with signs of skin infection at the entry site of the needle used to place the nerve block~4. Patients with signs of infection such as fever~5. Patients with history of inflammatory bowel disease of with signs of colitis~6. Patients with uncorrectable abnormal coagulation status (INR \>1.5 and plt \< 50000 without use of anticoagulation agents)~7. Patients with preexisting conditions, which, in the opinion of the investigator, interfere with the conduct of the study.~8. Patients who are uncooperative, cannot follow instructions, or who are unlikely to comply with follow-up appointments or fill-out the post-procedural pain questionnaires.~9. Patients with a mental state that may preclude completion of the study procedure or is unable to provide informed consent

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control group (Type: SHAM_COMPARATOR): Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
- Sup Hypogastric Nerve block group (Type: EXPERIMENTAL): Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.

Based on this trial design, predict the completion outcome and termination type (if applicable).